Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists

References

• Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the big bang. Cell. 2014;157:255–266.
   PubMed Web of Science ®Google Scholar
• Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81:687–693.
   PubMed Web of Science ®Google Scholar
• Gottlieb a, Canbay a. Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression. Cells. 2019;8:1358.
   Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328–357.
   PubMed Web of Science ®Google Scholar
• Wong T, Wong RJ, Gish RG. Diagnostic and treatment implications of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Gastroenterol Hepatol. 2019;15:83–89.
   Google Scholar
• Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152:598–607.e2.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology. 2019;69:2672–2682.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.e10.
   PubMed Web of Science ®Google Scholar
• Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265–1273.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155:443–457.e17.
   PubMed Web of Science ®Google Scholar
• Juluri R, Vuppalanchi R, Olson J, et al. Generalizability of the nonalcoholic steatohepatitis clinical research network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2011;45:55–58.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Network Open. 2019;2:e1912565.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Noureddin M, Vipani a, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113:1649–1659.
   PubMed Web of Science ®Google Scholar
• Mantovani a, Scorletti E, Mosca a, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;154170. DOI:10.1016/j.metabol.2020.154170
   PubMed Web of Science ®Google Scholar
• Targher G, Marchesini G, Byrne CD. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: causal association or epiphenomenon? Diabetes Metab. 2016;42:142–156.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.
   PubMed Web of Science ®Google Scholar
• Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13:509–520.
   PubMed Web of Science ®Google Scholar
• Zhu K, Wang Y, Shu P, et al. Increased serum levels of fetuin B in patients with coronary artery disease. Endocrine. 2017;58:97–105.
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Lonardo a, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589–600.
   PubMed Web of Science ®Google Scholar
• Stahl EP, Dhindsa DS, Lee SK, et al. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:948–963.
   PubMed Web of Science ®Google Scholar
• Allen AM, Hicks SB, Mara KC, et al. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity – a longitudinal cohort study. J Hepatol. 2019;71:1229–1236.
   PubMed Web of Science ®Google Scholar
• Mantovani a, Dauriz M, Byrne CD, et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. Metabolism. 2018;87:1–12.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Petroni ML, Cortez-Pinto H. Adipose tissue-associated cancer risk: is it the fat around the liver, or the fat inside the liver? J. Hepatol. 2019;71:1073–1075.
   Web of Science ®Google Scholar
• Gregg EW, The Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4:913–921.
   PubMed Web of Science ®Google Scholar
• Avgerinos KI, Spyrou N, Mantzoros CS, et al. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–135.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–378.e5.
   PubMed Web of Science ®Google Scholar
• Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ≥10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:1024–1030.
   PubMed Web of Science ®Google Scholar
• Salman AA, Sultan AAEA, Abdallah a, et al. Effect of weight loss induced by laparoscopic sleeve gastrectomy on liver histology and serum adipokine levels. J Gastroenterol Hepatol. 2020. DOI:10.1111/jgh.15029
   PubMed Web of Science ®Google Scholar
• Browning JD, Baker JA, Rogers T, et al. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr. 2011;93:1048–1052.
   PubMed Web of Science ®Google Scholar
• Kirk E, Reeds DN, Finck BN, et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology. 2009;136:1552–1560.
   PubMed Web of Science ®Google Scholar
• Pataky Z, Genton L, Spahr L, et al. Impact of hypocaloric hyperproteic diet on gut microbiota in overweight or obese patients with nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2016;61:2721–2731.
   PubMed Web of Science ®Google Scholar
• Anania C, Massimo Perla F, Olivero F, et al. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol. 2018;24:2083–2094.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59:138–143.
   PubMed Web of Science ®Google Scholar
• Berná G, Romero-Gomez M. The role of nutrition in non-alcoholic fatty liver disease: pathophysiology and management. Liver Int. 2020;40:102–108.
   PubMed Web of Science ®Google Scholar
• Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017;66:142–152.
   PubMed Web of Science ®Google Scholar
• Zhang HJ, He J, Pan LL, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern Med. 2016;176:1074–1082.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. J Am Coll Cardiol. 2014;63:2985–3023.
   PubMed Web of Science ®Google Scholar
• Boeckmans J, Natale a, Rombaut M, et al. Anti-NASH drug development hitches a lift on PPAR agonism. Cells. 2019;9:37.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.
   PubMed Web of Science ®Google Scholar
• Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus a randomized trial. Ann Intern Med. 2016;165:305–315.
   PubMed Web of Science ®Google Scholar
• Xi Y, Zhang Y, Zhu S, et al. PPAR-mediated toxicology and applied pharmacology. Cells. 2020;9:352.
   Web of Science ®Google Scholar
• Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352:i1541.
   PubMed Web of Science ®Google Scholar
• Portillo-Sanchez P, Bril F, Lomonaco R, et al. Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: a 36-month clinical trial. J Diabetes. 2019;11:223–231.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M, Tokushige K, et al. Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis. Int J Mol Sci. 2020;21:1907.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362–376.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71:495–509.
   PubMed Web of Science ®Google Scholar
• Jian H, Ai‐Min L. Will vitamin E be the hope of patients with NASH and advanced fibrosis? – the reliability is worth discussing. Hepatology. 2019. DOI:10.1002/hep.30603
   Google Scholar
• Bril F, Biernacki DM, Kalavalapalli S, et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019;42:1481–1488.
   PubMed Web of Science ®Google Scholar
• Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37.
   PubMed Web of Science ®Google Scholar
• Gerß J, Köpcke W. The questionable association of vitamin E supplementation and mortality - Inconsistent results of different meta-analytic approaches. Cell Mol Biol. 2009;55:1111–1120.
   Web of Science ®Google Scholar
• Abner EL, Schmitt FA, Mendiondo MS, et al. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011;4:158–170.
   PubMedGoogle Scholar
• Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2011;306:1549–1556.
   PubMed Web of Science ®Google Scholar
• Schürks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:1033.
   Google Scholar
• Cheng P, Wang L, Ning S, et al. Vitamin E intake and risk of stroke: a meta-analysis. Br J Nutr. 2018;120:1181–1188.
   PubMed Web of Science ®Google Scholar
• Tsou P, Wu C-J. Serum vitamin E levels of adults with nonalcoholic fatty liver disease: an inverse relationship with all-cause mortality in non-diabetic but not in pre-diabetic or diabetic subjects. J Clin Med. 2019;8:1057.
   Web of Science ®Google Scholar
• Sayiner M, Arshad T, Golabi P, et al. Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. Hepatol Int. 2020;14:556–566.
   PubMed Web of Science ®Google Scholar
• McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148–1155.
   PubMed Web of Science ®Google Scholar
• Nasr P, Ignatova S, Kechagias S, et al. Natural history of nonalcoholic fatty liver disease: a prospective follow‐up study with serial biopsies. Hepatol Commun. 2018;2:199–210.
   PubMed Web of Science ®Google Scholar
• Cholankeril G, Wong RJ, Hu M, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci. 2017;62:2915–2922.
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. a global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723–1730.
   PubMed Web of Science ®Google Scholar
• Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594–601.e1.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Tacke F, Sanyal AJ, et al. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. Hepatology. 2019;70:1424–1436.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Honda a, Ikegami T, et al. Human-specific dual regulations of FXR activation for reduction of fatty liver using in vitro cell culture model. J Clin Biochem Nutr. 2019;64:112–123.
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15/19 pathway. Dig Dis. 2015;33:327–331.
   PubMed Web of Science ®Google Scholar
• Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331:1621–1624.
   PubMed Web of Science ®Google Scholar
• Torra IP, Claudel T, Duval C, et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor. Mol Endocrinol. 2003;17:259–272.
   PubMedGoogle Scholar
• Wang Y, Nakajima T, Gonzalez FJ, et al. PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice. Int J Mol Sci. 2020;21:E2061.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang Q, Peng J, et al. Activation of farnesoid X receptor downregulates monocyte chemoattractant protein-1 in murine macrophage. Biochem Biophys Res Commun. 2015;467:841–846.
   PubMed Web of Science ®Google Scholar
• Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response. Hepatology. 2008;48:1632–1643.
   PubMed Web of Science ®Google Scholar
• Mouries J, Brescia P, Silvestri a, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216–1228.
   PubMed Web of Science ®Google Scholar
• Zhang D-Y, Zhu L, Liu H-N, et al. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. Drug Des Devel Ther. 2019;13:2249–2270.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569–3572.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Sanyal AJ, Loomba R, et al. REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019;84:105803.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–2196.
   PubMed Web of Science ®Google Scholar
• Han MAT, Altayar O, Hamdeh S, et al. Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:616–629.e26.
   PubMed Web of Science ®Google Scholar
• Hernandez ED, Zheng L, Kim Y, et al. Tropifexor‐mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents. Hepatol Commun. 2019;3:1085–1097.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Lopez P, Lawitz EJ, et al. Tropifexor (TXR), an FXR agonist for the treatment of NASH - interim results from first two parts of phase 2b study FLIGHT-FXR. Liver Meet; 2019; Boston, MA.
   Google Scholar
• Ratziu V, Sanyal a, Harrison SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology. 2020. DOI:10.1002/hep.31108
   Web of Science ®Google Scholar
• Patel K, Harrison SA, Elkashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a Phase 2 randomized controlled trial. Hepatology. 2020;72:58–71. .
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Gane E, Ruane PJ, et al. A combination of the ACC inhibitor GS-0976 (firsocostat) and the nonsteroidal FXR agonist GS-9674 (cilofexor) improves hepatic steatosis, biochemistry, and stiffness in patients with nonalcoholic steatohepatitis. International Liver Congress; 2019; Vienna, Austria.
   Google Scholar
• An P, Wei G, Huang P, et al. a novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020;40:1655–1669.
   PubMed Web of Science ®Google Scholar
• Rinella M. Enanta announces positive results of ARGON-1 study of its lead FXR agonist, EDP-305, for the treatment of NASH [Internet]; 2020 [cited 2020 Apr 26]. Available from: https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Announces-Positive-Results-of-ARGON-1-Study-of-its-lead-FXR-Agonist-EDP-305-for-the-Treatment-of-NASH/default.aspx
   Google Scholar
• Klucher K, Wang Y, Halcomb R, et al. a novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis. International Liver Congress; 2019; Vienna, Austria.
   Google Scholar
• Harrison SA, Bashir M, Shim-Lopez J, et al. MET409, a sustained FXR agonist, decreased hepatic fat and improved liver function without raising LDL‐C after 28 days in NASH patients. Liver Meet; 2019; Boston, MA.
   Google Scholar
• Radreau P, Joly S, Dubos C, et al. In vitro and in vivo characterization of EYP001 a novel potent and selective FXR agonist now in a phase 2 clinical trial in NASH. Liver Meet; 2019; Boston, MA.
   Google Scholar
• Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest. 2013;123:1513–1530.
   PubMed Web of Science ®Google Scholar
• Finn PD, Rodriguez D, Kohler J, et al. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in western diet-fed mice. Am J Physiol Gastrointest Liver Physiol. 2019;316:G412–G424.
   PubMed Web of Science ®Google Scholar
• Ghosh Laskar M, Eriksson M, Rudling M, et al. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III. J Intern Med. 2017;281:575–585.
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125–1131.
   PubMed Web of Science ®Google Scholar
• Papazyan R, Liu X, Liu J, et al. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. J Lipid Res. 2018;59:982–993.
   PubMed Web of Science ®Google Scholar
• Gautier T, De Haan W, Grober J, et al. Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. J Lipid Res. 2013;54:2195–2205.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yin L, Anderson J, et al. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem. 2010;285:3035–3043.
   PubMed Web of Science ®Google Scholar
• Claudel T, Sturm E, Duez H, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein a-I transcription via a negative FXR response element. J Clin Invest. 2002;109:961–971.
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Fuchs M, Freilich B, et al. CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 2019;39:2082–2093.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Heurtier a, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Kimura T, Fujimori N, et al. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol. Baishideng Publishing Group Co., Limited. 2019;25:163–177.
   PubMed Web of Science ®Google Scholar
• Piazzolla VA, Mangia a. Noninvasive diagnosis of NAFLD and NASH. Cells. 2020;9:1005.
   PubMed Web of Science ®Google Scholar
• Roth JD, Veidal SS, Fensholdt LKD, et al. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Sci Rep. 2019;9:9046.
   PubMed Web of Science ®Google Scholar
• Zhou J, Cui S, He Q, et al. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nat Commun. 2020;11. DOI:10.1038/s41467-019-14138-6
   Web of Science ®Google Scholar